Latest On Allena Pharmaceuticals, Inc (ALNA):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2022-07-19 13:06 EST | News | First two cohorts enrolled in Allena's phase 2a trial of gout & kidney disease treatment | N/A |  |
| 2022-07-06 02:19 EST | News | Allena Pharma reschedules special meeting to approve reverse stock split, shares fall | N/A | |
| 2022-05-12 12:17 EST | News | Nano cap stock Allena surges on heavy volume | N/A | |
| 2022-05-04 22:12 EST | News | Allena Pharmaceuticals $2.8M direct offering | N/A | |
| 2022-03-22 16:06 EST | News | Allena extends losses on plans to end trial for lead asset and financial concerns | N/A | |
About Allena Pharmaceuticals, Inc (ALNA):
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and moderate to severe chronic kidney diseases. Allena Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Newton, Massachusetts.
General
- Name Allena Pharmaceuticals, Inc
- Symbol ALNA
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 41
- Fiscal Year EndDecember
- IPO Date2017-11-02
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.allenapharma.com
Valuation
- Price/Book (Most Recent Quarter) 4.36
- Enterprise Value EBITDA 0.08
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.82
- Next Year EPS Estimate -$0.95
- Next Quarter EPS Estimate -$0.18
- Return on Assets -55%
- Return on Equity -165%
- Earnings Per Share -$2.01
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 90.44 million
- EBITDA -42249000
- Analyst Target Price $5.8
- Book Value Per Share $0.44
Share Statistics
- Shares Outstanding 50.25 million
- Shares Float 47.76 million
- % Held by Insiders 388%
- % Held by Institutions 42.24%
- Shares Short 663917
- Shares Short Prior Month 902093
- Short Ratio 0.15
- Short % of Float 2%
- Short % of Shares Outstanding 1%
Technicals
- Beta 2.31
- 52 Week High $3.39
- 52 Week Low $0.78
- 50 Day Moving Average 1.78
- 200 Day Moving Average 1.49
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Allena Pharmaceuticals, Inc (ALNA) Dividend Calendar:
Allena Pharmaceuticals, Inc (ALNA) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Allena Pharmaceuticals, Inc (ALNA) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Allena Pharmaceuticals, Inc (ALNA) Chart:
Allena Pharmaceuticals, Inc (ALNA) News:
Below you will find a list of latest news for Allena Pharmaceuticals, Inc (ALNA) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Allena Pharmaceuticals, Inc (ALNA) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest ALNA Trades:
Allena Pharmaceuticals, Inc (ALNA) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-06 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-10-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-05 | 8-K (Current report) | |
| 2020-10-05 | DEF 14A (Other definitive proxy statements) | |
| 2020-10-05 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
| 2020-10-01 | 8-K (Current report) | |
| 2020-08-28 | 8-K (Current report) | |
| 2020-08-05 | 8-K (Current report) | |
| 2020-08-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-29 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-07-29 | 8-K (Current report) | |
| 2020-07-28 | FWP (Filing under Securities Act Rules 163/433 of free writing prospectuses) | |
| 2020-07-27 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-07-27 | FWP (Filing under Securities Act Rules 163/433 of free writing prospectuses) | |
| 2020-06-09 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-06-09 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-06-05 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-06-05 | 8-K (Current report) | |
| 2020-06-03 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-05-29 | 4 (Statement of changes in beneficial ownership of securities) | |
Allena Pharmaceuticals, Inc (ALNA) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Allena Pharmaceuticals, Inc (ALNA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 388%
Institutional Ownership: 4224%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2018-05-09 | EDWARD WHOLIHAN | Chief Financial Officer | Buy | 25,000.00 | 1.59 | 39,750.00 | 25,000.00 | |